Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 6.48 5.81 5.97 0.00 0.00 0.00 0.00
Piotroski F-Score
4 6 4 5 5 6 6 4 5 6
P/S ratio
2.51 1.97 3.02 1.49 2.98 2.80 7.42 2.67 4.01 8.36
Altman Z-Score
5.63 4.68 5.91 6.78 19.45 8.36 24.02 11.69 14.85 26.24
P/FCF ratio
0.00 0.00 156.59 3.92 5.75 11.21 55.67 0.00 0.00 243.81
Altman Z″-Score (non-manufacturers)
14.32 15.74 14.58 16.78 18.68 11.73 14.64 19.55 18.66 15.65
P/Operating CF
(10.35) 22.32 58.42 27.79 38.37 8.81 (2,080.57) 73.25 (60.46) 121.90
Beneish M-Score
(2.35) (1.99) (2.55) (3.70) (1.34) 8.62 (1.53) (2.66) (2.97) (0.29)
P/B ratio
0.73 0.49 0.77 0.73 2.54 2.08 2.92 1.11 1.39 2.81
Price to Tangible BV
0.80 0.54 0.90 0.95 2.74 2.08 2.92 1.11 1.39 2.81
EV/Sales
1.53 1.13 1.62 0.67 2.55 2.13 6.63 1.22 2.59 7.22
EV/EBITDA
0.00 0.00 0.00 1.93 3.64 3.06 120.87 0.00 0.00 61.37
EV/Operating CF
(4.85) 15.26 17.37 1.65 4.70 6.39 39.11 (38.45) 36.48 29.97
EV/FCF
(3.97) (16.96) 84.22 1.78 4.91 8.52 49.77 (7.40) (12.06) 210.52
Quick Ratio
4.95 4.49 6.51 6.57 5.60 3.71 9.35 13.51 10.16 7.61
Current Ratio
6.48 4.85 6.96 7.13 5.81 4.02 9.96 14.44 10.98 7.88
Net Debt/EBITDA
4.66 4.73 7.99 (2.37) (0.63) (0.97) (15.84) 11.89 19.14 (9.70)
Debt/Assets
0.00% 0.00% 0.00% 1.08% 1.18% 2.14% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.01 0.01 0.03 0.00 0.00 0.00 0.00
Asset Turnover
0.27 0.23 0.22 0.46 1.00 1.07 0.46 0.38 0.33 0.57
Operating CF/Net income
1.68 (0.49) (0.16) 1.77 1.06 0.66 (13.42) 0.12 (0.53) (0.82)
Capex/Depreciation
(1.19) (2.06) (0.15) (0.49) (1.28) (9.20) (0.53) (1.15) (2.55) (3.06)
Interest Coverage
(1,214.61) 434.81 (400.67) 176.24 519.96 193.44 (0.49) (8.77) (7.62) —
ROE
(5.41%) (3.78%) (13.97%) 11.77% 58.48% 65.72% (0.61%) (10.65%) (4.62%) (17.94%)
ROA
(4.97%) (3.48%) (12.80%) 10.76% 51.27% 54.31% (0.58%) (10.09%) (4.36%) (16.74%)
ROIC
(7.39%) (5.30%) (17.23%) 14.71% 57.83% 63.62% (0.49%) (15.75%) (7.86%) 1.71%
Return on Tangible Assets
(10.47%) (11.06%) (32.38%) 23.09% 89.18% 49.41% (1.05%) (12.96%) (6.75%) (18.40%)
Average Days of Receivables
95.88 88.87 64.53 31.11 51.08 159.13 73.55 101.68 78.05 87.16
Research and Development Expense of Revenue
16.71% 17.22% 14.33% 4.67% 2.44% 2.75% 20.10% 25.92% 22.55% 19.47%
Selling, General and Administrative Expense of Revenue
49.60% 43.87% 45.11% 24.23% 7.57% 7.15% 37.85% 47.73% 50.39% 38.73%
Intangible Assets out of Total Assets
0.07 0.08 0.13 0.21 0.07 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
12.27% 15.69% 14.84% 5.27% 1.60% 1.93% 9.87% 10.79% 11.31% 25.47%
Graham Net Nets
0.55 0.47 0.47 0.55 0.17 0.33 0.13 0.65 0.40 0.15
Graham Number
0.00 0.00 0.00 67.01 124.26 70.16 0.00 0.00 0.00 0.00
Earnings Yield
(7.46%) (7.63%) (19.26%) 15.43% 17.21% 16.74% (0.11%) (9.89%) (3.58%) (3.98%)
Free Cash Flow Yield
(15.36%) (3.39%) 0.64% 25.48% 17.40% 8.92% 1.80% (6.15%) (5.36%) 0.41%
Revenue per Share
10.48 9.38 9.71 20.57 33.75 18.58 1.74 1.19 1.06 1.33
Operating CF per Share
(3.30) 0.70 0.91 8.42 18.31 6.20 0.29 (0.04) 0.08 0.32
Capex per Share
(0.73) (1.32) (0.72) (0.61) (0.81) (1.55) (0.06) (0.16) (0.30) (0.28)
Free Cash Flow per Share
(4.04) (0.63) 0.19 7.81 17.51 4.65 0.23 (0.20) (0.23) 0.05
Cash per Share
10.92 8.54 14.24 17.48 15.32 13.19 1.51 1.73 1.49 1.52
Shareholders Equity per Share
35.96 37.35 38.05 42.19 39.65 25.09 4.42 2.85 3.05 3.97
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
35.96 37.35 38.05 42.19 39.65 25.09 4.42 2.85 3.05 3.97
Free Cash Flow
(124.21) (18.94) 5.57 235.16 514.80 105.51 4.34 (3.51) (4.02) 0.63
Working Capital
465.52 280.67 434.83 539.77 506.65 393.50 33.36 36.81 29.93 22.82
Capital Expenditures
(22.57) (40.00) (21.43) (18.36) (23.78) (35.12) (1.18) (2.83) (5.36) (3.78)
Net Current Asset Value
443.68 262.77 405.80 511.70 499.12 392.54 31.10 36.79 29.92 22.58
EV/EBIT
0.00 0.00 0.00 2.34 3.74 3.10 0.00 0.00 0.00 143.79
Capex to Sales
0.07 0.14 0.07 0.03 0.02 0.08 0.04 0.13 0.29 0.21
Price to Operating Income
0.00 0.00 0.00 5.17 4.38 4.07 0.00 0.00 0.00 166.52
Other line items
Depreciation/Fixed assets
0.17 0.18 1.71 0.46 0.30 0.10 0.37 0.38 0.29 0.20
Cash ROIC
(8.61%) (1.37%) 0.36% 12.98% 31.55% 11.94% 3.90% (4.27%) (4.99%) 0.83%
Accounts Receivable Turnover
4.20 4.72 5.57 6.46 6.15 4.43 5.20 4.29 4.48 5.64
Accounts Payable Turnover
10.36 10.45 9.61 11.57 9.18 6.40 9.75 6.29 3.53 4.38
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
35.50 38.03 30.34 33.44 34.71 107.65 40.91 44.80 89.17 149.65
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
76.89 60.08 51.94 95.83 161.38 95.21 6.25 4.98 4.18 3.24
Average Payables
18.51 16.86 19.23 21.79 23.49 14.03 1.45 1.70 2.42 1.54
Average Assets
1,216.74 1,227.65 1,310.69 1,332.39 989.59 394.61 71.33 55.54 57.61 31.94
Average Common Equity
1,117.94 1,131.22 1,201.58 1,217.88 867.63 326.08 66.96 52.67 54.33 29.81

Fold the line items

Columns are period end dates